Global scenario of microbes, infections, antibiotics and resistance - By Dr. A.J. Tamhankar

-How A Novel Class Of Antibodies Inhibits HIV Infection
-Cubist Pharmaceuticals Enrolls 1st Subject In Phase 2 Trial For Therapy To Treat Clostridium -Difficile-Associated Diarrhea, Or CDAD
-FDA Provides Information To Consumers About The Ingredient Triclosan-New Model Tracks The Immune Response To A T
-Cempra Announces Expansion Of Clinical Management Team To Advance Leading Antibacterial Clinical Programs TAKSTA(TM) And CEM-101-Optimer Pharmaceuticals Announces Presentations Of Data From The Fidaxomicin Phase 3 Trials At ECCMID-Pathogenic Fungus Loves Brain Sugar